Herceptin Market Report 2026

The herceptin market size has grown strongly in recent years. It will grow from $7.48 billion in 2025 to $7.92 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to expansion of her2-positive cancer diagnosis, widespread clinical acceptance of trastuzumab, growth in oncology infusion infrastructure, availability of biologic manufacturing capabilities, inclusion of herceptin in standard treatment guidelines.

The herceptin market size is expected to see strong growth in the next few years. It will grow to $9.92 billion in 2030 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to increasing biosimilar competition, rising demand for affordable biologic therapies, expansion of targeted oncology pipelines, growing adoption of personalized cancer treatment, increasing investment in biologic drug innovation. Major trends in the forecast period include increasing adoption of biosimilar trastuzumab products, growing use of subcutaneous formulations, expansion of combination therapy regimens, rising focus on cost-effective biologic treatments, enhanced monitoring of treatment outcomes.

The rising incidence of breast cancer is expected to drive the growth of the herceptin market in the coming years. Breast cancer is a disease in which malignant cells develop in breast tissue, most commonly originating in the milk ducts or lobules. It encompasses conditions such as invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), and HER2-positive breast cancer. The increase in breast cancer cases is partly attributed to lifestyle-related factors, including higher alcohol consumption, unhealthy dietary habits, and reduced physical activity, all of which elevate risk levels. As the number of diagnosed breast cancer cases grows, particularly those involving HER2-positive tumors, the demand for effective targeted treatments such as herceptin continues to increase. For example, in January 2025, according to the American Cancer Society, a US-based cancer organization, approximately 319,750 new breast cancer cases are projected to be reported in 2025, along with an estimated 42,680 deaths associated with the disease. Consequently, the growing prevalence of breast cancer is contributing to the expansion of the herceptin market.

Leading companies operating in the herceptin market are advancing new treatment options, including innovative biosimilar products, to improve patient access and enhance treatment outcomes for HER2-positive cancers. Innovative biosimilars are highly similar alternatives to approved biologic medicines, developed using advanced biotechnological processes to achieve comparable safety, effectiveness, and quality. For instance, in April 2024, Accord BioPharma Inc., a US-based pharmaceutical company, obtained approval from the U.S. Food and Drug Administration for HERCESSI (trastuzumab-strf), a biosimilar to herceptin (trastuzumab), indicated for the treatment of HER2-overexpressing breast and gastric cancers. Biosimilar products such as HERCESSI provide efficacy and safety comparable to reference biologics while offering more cost-efficient treatment options.

In October 2025, Teva Pharmaceutical Industries Ltd., an Israel-based global pharmaceutical company, entered into a licensing agreement with Prestige Biopharma to commercialize Tuznue in Europe. This agreement is intended to broaden Tuznue’s market reach, improve patient access to innovative therapies, and reinforce the competitive positions of both companies within the European biopharmaceutical market. Prestige Biopharma is a US-based biopharmaceutical company that focuses on the development and commercialization of biologic therapies.

Major companies operating in the herceptin market are Roche Holding AG, Pfizer Inc., Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd, Biocon Limited, Dr. Reddy’s Laboratories, Celltrion Inc., Samsung Biologics, Fresenius Kabi, Intas Pharmaceuticals Ltd, Zydus Lifesciences Ltd, AryoGen Pharmed, Shanghai Henlius Biotech Inc., Prestige Biopharma Pte Ltd, Alvotech, Coherus BioSciences, BioXpress Therapeutics, Amneal Pharmaceuticals, Novartis AG.

North America was the largest region in the herceptin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the herceptin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the herceptin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the herceptin market by increasing costs of imported biologic raw materials, cell culture media, formulation components, and specialized cold-chain logistics required for trastuzumab distribution. Hospitals and specialty pharmacies in North America and Europe are most affected due to reliance on imported biologics, while Asia-Pacific faces pricing pressure on biosimilar exports. These tariffs are raising treatment and reimbursement costs. However, they are also encouraging domestic biologics manufacturing, regional biosimilar production, and localized supply chains for oncology biologic drugs.

The herceptin market research report is one of a series of new reports that provides herceptin market statistics, including herceptin industry global market size, regional shares, competitors with a herceptin market share, detailed herceptin market segments, market trends and opportunities, and any further data you may need to thrive in the herceptin industry. This herceptin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Herceptin, also referred to as trastuzumab, is a monoclonal antibody indicated for the treatment of HER2-positive breast and gastric cancers. It works by selectively targeting the HER2/neu receptor, which is involved in the proliferation of cancer cells. By attaching to this receptor, herceptin suppresses tumor cell growth and marks the cells for elimination by the immune system.

The primary herceptin product categories include biologics and biosimilars. Biologics are complex, large-molecule therapies produced from living organisms and are used in the treatment of a range of conditions, including cancer. The key payer segments include commercial, private, and public entities. Herceptin is used across multiple applications, such as breast cancer and gastric cancer, and is distributed through various channels, including hospital pharmacies and specialty pharmacies.

The herceptin market consists of sales of trastuzumab, trastuzumab deruxtecan, and ado-trastuzumab emtansine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.